Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Designation crawled time : 13:00 save search
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
SNGX | $0.4 -1.43% -1.15% 410K
|
Health Technology
|
| O: 75.34%
H: 37.73%
C: -30.58%
fda drug marburg infection designation for grants
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Published: 2024-04-11 (Crawled : 13:00) - globenewswire.com
CADL | $5.91 6.68% 6.73% 440K
|
|
| O: 25.49%
H: 23.75%
C: 13.75%
can-2409 fda drug cancer pancreatic treatment designation for therapeutics
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
Published: 2024-03-20 (Crawled : 13:00) - globenewswire.com
CELU | News F | $3.21 4.9% 7.27% 19K
|
|
| O: 4.02%
H: 0.74%
C: 0.74%
pda-002 fda drug designation
The Shyft Group Achieves Ford Pro Upfitter Designation
Published: 2024-03-06 (Crawled : 13:00) - globenewswire.com
F | News | $12.94 0.47% 0.46% 57M
|
Consumer Durables
|
| O: -0.48%
H: 0.4%
C: -1.12%
SHYF | $11.03 -0.72% -0.63% 290K
|
Producer Manufacturing
|
| O: 1.2%
H: 2.56%
C: 1.38%
pro group designation ford
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
Published: 2024-02-27 (Crawled : 13:00) - biospace.com/
NUVL | $67.6 4.82% 4.54% 490K
|
|
| O: 1.49%
H: 1.65%
C: 1.24%
nvl-520 fda designation therapy
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
Published: 2024-02-20 (Crawled : 13:00) - globenewswire.com
PEPG | $11.72 2.9% 3.06% 14K
|
|
| O: -1.08%
H: 4.73%
C: 0.29%
fda treatment designation
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROME
Published: 2024-02-20 (Crawled : 13:00) - prnewswire.com
HRMY | $28.85 -1.7% -1.56% 430K
|
Health Technology
|
| O: -1.66%
H: 1.26%
C: -0.69%
drug food designation
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
Published: 2024-02-20 (Crawled : 13:00) - globenewswire.com
IMRX | $1.63 -5.23% -5.52% 320K
|
|
| O: 6.97%
H: 2.83%
C: -4.25%
fda cancer pancreatic designation
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
Published: 2024-02-15 (Crawled : 13:00) - biospace.com/
IONS | $41.84 1.88% 1.86% 630K
|
Health Technology
|
| O: -1.53%
H: 3.16%
C: -6.29%
fda drug designation
Johnson & Johnson's nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
Published: 2024-02-09 (Crawled : 13:00) - prnewswire.com
JNJ | News | $149.56 0.3% -0.17% 6.9M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
fda disease granted treatment risk designation therapy
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
Published: 2024-01-23 (Crawled : 13:00) - globenewswire.com
FDMT M | $24.81 -5.99% -6.54% 570K
|
Health Technology
|
| O: 2.08%
H: 3.85%
C: 1.65%
fda rare lung disease treatment fibrosis designation
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Published: 2024-01-23 (Crawled : 13:00) - globenewswire.com
RZLT 4 | $2.86 -19.21% -23.78% 940K
|
Technology Services
|
| O: 2.04%
H: 9.0%
C: 2.0%
rz358 innovation group treatment designation hypoglycemia
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
Published: 2024-01-16 (Crawled : 13:00) - prnewswire.com
PGEN | $1.4 1.45% 1.43% 510K
|
Health Technology
|
| O: 2.92%
H: 0.0%
C: -7.45%
prgn-2012 drug respiratory treatment designation
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Published: 2024-01-16 (Crawled : 13:00) - globenewswire.com
SLDB | $9.11 0.77% 0.44% 300K
|
Health Technology
|
| O: 7.52%
H: 1.21%
C: -3.5%
sgt-003 fda drug candidate granted designation duchenne therapy
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis
Published: 2024-01-04 (Crawled : 13:00) - globenewswire.com
PHGE | $0.3465 17.42% -7.04% 210K
|
Health Technology
|
| O: -0.37%
H: 6.26%
C: 0.04%
bx004 drug food infection treatment fibrosis designation
Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease
Published: 2024-01-02 (Crawled : 13:00) - biospace.com/
BTTX | $0.006 -1.64% -65.02% 340K
|
|
| O: 4.1%
H: 0.3%
C: -10.0%
fda device liver disease treat designation therapeutics platform submission
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
Published: 2023-12-21 (Crawled : 13:00) - globenewswire.com
SLS | $1.63 5.84% 4.64% 2M
|
Health Technology
|
| O: 2.46%
H: 4.0%
C: -8.0%
sls009 fda drug t-cell treatment designation lymphomas
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
Published: 2023-12-21 (Crawled : 13:00) - globenewswire.com
FDMT M | $24.81 -5.99% -6.54% 570K
|
Health Technology
|
| O: 3.04%
H: 7.13%
C: 4.18%
fda rmat first genetic treatment designation advanced therapy
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
Published: 2023-12-21 (Crawled : 13:00) - globenewswire.com
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
BNTX | News | $88.49 0.55% 0.59% 330K
|
Health Technology
|
| O: 0.67%
H: 1.46%
C: 0.08%
bnt323 fda candidate cancer designation therapy
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma
Published: 2023-12-12 (Crawled : 13:00) - globenewswire.com
VIRX | $0.8478 -3.66% -5.9% 86K
|
Manufacturing
|
| O: 1.63%
H: 1.94%
C: -7.78%
fda drug granted treatment designation therapeutics
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.